Citations

Clear

3138 citation(s) found for "Smith, AM".

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
Wagemann, Olivia , Shi, Xinyu , Bittner, Tobias , Scelsi, Marzia A. , Farlow, Martin R. , Clifford, David B. , Santacruz, Anna , Aschenbrenner, Andrew J. , Hassenstab, Jason , Gordon, Brian A. , Coalier, Kelley A., Perrin, Richard J., Xiong, Chengjie , Li, Yan , Morris, John C. , Lah, James J., Berman, Sarah , Roberson, Erik D. , Dyck, Christopher H. van, Gauthier, Serge , Pariente, Jérémie , Mummery, Catherine J. , Day, Gregory S. , Ringman, John M. , Méndez, Patricio Chrem, Fox, Nick C. , Okhravi, Hamid , Chhatwal, Jasmeer P. , Xiong, Chengjie , Sims, John R. , Holdridge, Karen C. , Proctor, Nicholas K. , Yaari, R. , Andersen, Scott W. , Mancini, Michele , Unit, Dominantly Inherited Alzheimer Network–Trials, Daniels, Alisha , Courtney, Laura, Lu, Ruijin , Gremminger, Emily, Franklin, Erin , Jerome, Gina, Herries, Elizabeth, Baker, Bryce, Minton, Matthew, Goate, Alison , Picarello, Danielle M. , Hornbeck, Russ C. , Chen, Allison , Chen, Charles D., Jarman, Steve, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Sabaredzovic, Edita, Smith, Hunter , Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Nadkarni, Neelesh K. , Graff‐Radford, Neill R. , Huey, Edward D. , Salloway, Stephen , Bechara, Jacob , Ryan, Natalie S. , Laske, Christoph , Hofmann, Anna, Kuder-Buletta, Elke, Gräber‐Sultan, Susanne, Obermueller, Ulrike, Roedenbeck, Yvonne, Sánchez‐Valle, Raquel , Vázquez, Silvia , Leon, Yudy Milena, Ramírez, Laura, Seyfried, Nicholas T. , Fagan, Anne M. , Mori, Hiroshi , Gordon, Brian A , Roberson, Erik , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Goate, Alison M , Berman, Sarah , Liu, Haiyan , Wang, Guoqiao , Supnet, Charlene , Benzinger, Tammie L.S. , Cruchaga, Carlos , Ibanez, Laura , Li, Yan, Dyck, Christopher H. van , Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Brooks, William S. , George‐Hyslop, Peter St , Suzuki, Kazushi , Jucker, Mathias , Mancini, Michele, Llibre‐Guerra, Jorge J. , Bateman, Randall J. , McDade, Eric , Unit, Dominantly Inherited Alzheimer Network–Trials, Xu, Xiong, Stauber, Jennifer, Renton, Alan , Flores, Shaney , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wáng, Qīng , Smith, Jennifer A. , Stout, Sarah Holtz , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Noble, James M. , Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Schofield, Peter R. , Martins, Ralph N. , Cash, David M. , Vöglein, Jonathan , Lee, Jae‐Hong , Roh, Jee Hoon , Rosa-Neto, Pedro , Allegri, Ricardo , Surace, Ezequiel , Lopera, Francisco Javier , Aguillon, David , Levey, Allan I. , Johnson, Erik C. B. , Masters, Colin L.

Mayo Clinic

JAMA Neurology | April 29, 2024 | Volume: 81 | Issue: 6 | Pages: 582

10.1001/jamaneurol.2024.0991 | PMID 38683602 Get It

Importance Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD). Objective To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment. Design, Setting, and Participants From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted from April to June 2023. DIAN-TU-001 spans 25 study sites in 7 countries. Biofluids and neuroimaging from carriers of DIAD gene variants in the gantenerumab, solanezumab, and placebo groups were analyzed. Interventions In 2016, initial dosing of gantenerumab, 225 mg (subcutaneously every 4 weeks) was increased every 8 weeks up to 1200 mg. In 2017, initial dosing of solanezumab, 400 mg (intravenously every 4 weeks) was increased up to 1600 mg every 4 weeks. Main Outcomes and Measures Longitudinal changes in CSF levels of neurogranin, soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase 3–like 1 protein (YKL-40), glial fibrillary acidic protein (GFAP), neurofilament light protein (NfL), and plasma levels of GFAP and NfL. Results Of 236 eligible participants screened, 43 were excluded. A total of 142 participants (mean [SD] age, 44 [10] years; 72 female [51%]) were included in the study (gantenerumab, 52 [37%]; solanezumab, 50 [35%]; placebo, 40 [28%]). Relative to placebo, gantenerumab significantly reduced CSF neurogranin level at year 4 (mean [SD] β = −242.43 [48.04] pg/mL; P < .001); reduced plasma GFAP level at year 1 (mean [SD] β = −0.02 [0.01] ng/mL; P = .02), year 2 (mean [SD] β = −0.03 [0.01] ng/mL; P = .002), and year 4 (mean [SD] β = −0.06 [0.02] ng/mL; P < .001); and increased CSF sTREM2 level at year 2 (mean [SD] β = 1.12 [0.43] ng/mL; P = .01) and year 4 (mean [SD] β = 1.06 [0.52] ng/mL; P = .04). Solanezumab significantly increased CSF NfL (log) at year 4 (mean [SD] β = 0.14 [0.06]; P = .02). Correlation analysis for rates of change found stronger correlations between CSF markers and fluid markers with Pittsburgh compound B positron emission tomography for solanezumab and placebo. Conclusions and Relevance This randomized clinical trial supports the importance of fibrillar amyloid reduction in multiple AD-related processes of neuroinflammation and neurodegeneration in CSF and plasma in DIAD. Additional studies of antiaggregated amyloid therapies in sporadic AD and DIAD are needed to determine the utility of nonamyloid biomarkers in determining disease modification. Trial Registration ClinicalTrials.gov Identifier: NCT04623242
Survival outcomes in pediatric patients with metastatic Ewing sarcoma who achieve a rapid complete response of pulmonary metastases
Reiter, Audra J. , Huang, Lynn , Craig, Brian T. , Davidoff, Andrew M. , Coggins, Jordan , Smith, Jasmine , Aldrink, Jennifer H. , Bergus, Katherine , MacArthur, Taleen A. , Polites, Stephanie F. , Boehmer, Chloé , Brungardt, Joseph G. , Arkin, Cameron, Gourmel, Antoine , Piché, Nelson , Wallace, Marshall, Liang, Jiancong , Lovvorn, Harold N. , Petroze, Robin T. , Gillies, Gwendolyn S. , Marquart, John , Becktell, Kerri , Favela, Juan , Rich, Barrie S. , Glick, Richard D. , Seemann, Natashia M. , Davidson, Jacob , Wilson, Claire A. , Roach, Jonathan P. , Doyle, Kathleen , Coakley, Brian A. , Emengo, Pamela, Merola, Pamela R., Grant, Christa N. , Tirumani, Anuritha, Dasgupta, Roshni , Wallace, Marshall W. , Aldrink, Jennifer H , Bergus, Katherine C , MacArthur, Taleen A , Malek, Marcus M , Kastenberg, Zachary J , Piche, Nelson , Becktell, Kerri , Seemann, Natashia M , Tracy, Elisabeth T , Lautz, Timothy , Dasgupta, Roshni , Arkin, Cameron , Talbot, Lindsay J , Malek, Marcus M. , Rinehardt, Hannah , Kastenberg, Zachary J. , Wallace, Marshall, Le, Hau D. , Brown, Erin G. , Tracy, Elisabeth T. , Moya‐Mendez, Mary E. , Lautz, Timothy B.

Mayo Clinic

Pediatric Blood & Cancer | April 29, 2024 | Volume: 71 | Issue: 7 | Pages: No page available

10.1002/pbc.31026 | PMID 38679864 Get It

Abstract Purpose Our objectives were to compare overall survival (OS) and pulmonary relapse between patients with metastatic Ewing sarcoma (EWS) at diagnosis who achieve rapid complete response (RCR) and those with residual pulmonary nodules after induction chemotherapy (non‐RCR). Patients and methods This retrospective cohort study included children under 20 years with metastatic EWS treated from 2007 to 2020 at 19 institutions in the Pediatric Surgical Oncology Research Collaborative. Chi‐square tests were conducted for differences among groups. Kaplan–Meier curves were generated for OS and pulmonary relapse. Results Among 148 patients with metastatic EWS at diagnosis, 61 (41.2%) achieved RCR. Five‐year OS was 71.2% for patients who achieved RCR, and 50.2% for those without RCR ( p = .04), and in multivariable regression among patients with isolated pulmonary metastases, RCR (hazards ratio [HR] 0.42; 95% confidence interval [CI]: 0.17–0.99) and whole lung irradiation (WLI) (HR 0.35; 95% CI: 0.16–0.77) were associated with improved survival. Pulmonary relapse occurred in 57 (37%) patients, including 18 (29%) in the RCR and 36 (41%) in the non‐RCR groups ( p = .14). Five‐year pulmonary relapse rates did not significantly differ based on RCR (33.0%) versus non‐RCR (47.0%, p = .13), or WLI (38.8%) versus no WLI (46.0%, p = .32). Discussion Patients with EWS who had isolated pulmonary metastases at diagnosis had improved OS if they achieved RCR and received WLI, despite having no significant differences in rates of pulmonary relapse.
INHIBITORS OF INORGANIC POLYPHOSPHATE AND NUCLEIC ACIDS ATTENUATE IN VITRO THROMBIN GENERATION IN PLASMA FROM TRAUMA PATIENTS
Goswami, Julie , Navarro, Sergio M. , Vappala, Sreeparna , La, Chanel C. , Yudin, Nikoli , Zietlow, John , Morrissey, James H. , Spears, Grant M. , Bailey, Kent R. , Dong, Jing‐fei , Kozar, Rosemary A. , Kizhakkedathu, Jayachandran N. , Park, Myung S., MacArthur, Taleen A. , Navarro, Sergio Michael , Smith, Stephanie A.

Mayo Clinic

Shock | April 25, 2024 | Volume: 61 | Issue: 6 | Pages: 848-854

10.1097/shk.0000000000002362 | PMID 38662595 Get It

ABSTRACT Background: Inorganic polyphosphate (polyP) is a procoagulant polyanion. We assessed the impact of polyP inhibition on thrombin generation after trauma using the novel polyP antagonists, macromolecular polyanion inhibitor 8 (MPI 8), and universal heparin reversal agent 8 (UHRA-8). Methods: Plasma thrombin generation (calibrated automated thrombogram, CAT), in 56 trauma patients and 39 controls +/− MPI 8 and UHRA-8 (50 μg/mL), was expressed as lag time (LT, minutes), peak height (PH, nM), and time to peak (ttPeak, minutes), with change in LT (ΔLT) and change in ttPeak (ΔttPeak) quantified. Results expressed in median and quartiles [Q1, Q3], Wilcoxon matched-pairs testing, P < 0.05 significant. Results: Trauma patients had greater baseline PH than controls (182.9 [121.0, 255.2]; 120.5 [62.1, 174.8], P < 0.001). MPI 8 treatment prolonged LT and ttPeak in trauma (7.20 [5.88, 8.75]; 6.46 [5.45, 8.93], P = 0.020; 11.28 [8.96, 13.14]; 11.00 [8.95, 12.94], P = 0.029) and controls (7.67 [6.67, 10.50]; 6.33 [5.33, 8.00], P < 0.001; 13.33 [11.67, 15.33]; 11.67 [10.33, 13.33], P < 0.001). UHRA-8 treatment prolonged LT and ttPeak and decreased PH in trauma (9.09 [7.45, 11.33]; 6.46 [5.45, 8.93]; 14.02 [11.78, 17.08]; 11.00 [8.95, 12.94]; 117.4 [74.5, 178.6]; 182.9 [121.0, 255.2]) and controls (9.83 [8.00, 12.33]; 6.33 [5.33, 8.00]; 16.67 [14.33, 20.00]; 11.67 [10.33, 13.33]; 55.3 [30.2, 95.9]; 120.5 [62.1, 174.8]), all P < 0.001. Inhibitor effects were greater for controls (greater ΔLT and ΔttPeak for both inhibitors, P < 0.001). Conclusion: PolyP inhibition attenuates thrombin generation, though to a lesser degree in trauma than in controls, suggesting that polyP contributes to accelerated thrombin generation after trauma.
A Patient with Unexpected Golden Brown Tubular Staining
Bhasin, Bhavna , Bhasin-Chhabra, Bhavna , Smith, Maxwell L.

Mayo Clinic

Kidney360 | April 25, 2024 | Volume: 5 | Issue: 4 | Pages: 631-632

10.34067/kid.0000000000000366 | PMID 38662537 Get It

Abstract 208: Achieving the 2010 AHA Guideline Metrics for CPR Quality Is Associated with Improved Survival from Out-of-Hospital Cardiac Arrest
Bobrow, Bentley J., Stolz, Uwe, Vadeboncoeur, Tyler F. , Silver, Annemarie, Pyers, Keith, Venuti, Mark, Smith, Gary A. , Ewy, Gordon A. , Group, SHARE Rsch, Spaite, Daniel W. , Panchal, Ashish R. , Group, SHARE Rsch

Mayo Clinic

Circulation | April 23, 2024 | Volume: 124 | Issue: suppl_21 | Pages: No page available

10.1161/circ.124.suppl_21.a208 Get It

Objective: The 2010 AHA Guidelines stress the need for minimally interrupted, high quality CPR. We performed a prospective, before/after trial to determine if real-time audiovisual feedback (RTAVF) along with scenario-based training (SBT) would 1) achieve the 2010 CPR targets and 2) improve survival from OHCA. Methods: Data obtained from EMS care forms and defibrillators (E Series, ZOLL) from 2 EMS agencies (population base-500,000). Phase 1 (P1, before): 18 months of baseline data with the RTAVF mode disabled (9/08-3/10). Interventions: 1) Guideline-based SBT of ~450 EMTs, 2) RTAVF enabled, 3) EMT post-code debriefings. Phase 2 (P2, after): 8 months following implementation of interventions (5/10-12/10). For univariate analyses we used Fisher's exact test (proportions), t-test (means) or Kruskal-Wallis test (medians). To estimate odds ratios for survival to hospital discharge we used multivariable logistic regression and assessed final model diagnostics, fit, and discrimination. Results: The final analysis included 284 adult OHCAs (P1-176, P2-108). Mean age 65.4 years (SD ± 15.3) with 66.6% males. Quality measures improved significantly from P1 to P2: Median (Interquartile range) chest compression (CC) rate-121 CC/min (109-135) to 101 CC/min (100-106), p <0.001; CC depth-1.73 in. (1.42-1.97) to 2.09 in. (1.92-2.3), p <0.001; CC fraction-66.5% (59.3-75.9%) to 84.0% (77.8-88.7%), p <0.001. All-rhythms survival increased significantly (p=0.034) from P1 to P2 (18/176, 10.2% vs. 23/108, 19.4%), an absolute survival increase of 9.2% (95% CI: 0.5%-17.9%). Crude odds ratio for survival for P2 vs. P1 was 2.1 (95% CI: 1.1-4.2) and adjusted odds ratio was 5.8 (95% CI: 1.8-18.9), after controlling for confounders including age, sex, location, witnessed arrest, initial rhythm, and therapeutic hypothermia. Survival for arrests with a shockable rhythm was 27.7% (18/65) for P1 and 53.9% (14/26) for P2 (p=0.028). Conclusion: RTAVF combined with SBT was associated with a significant improvement in the proportion of compressions meeting the 2010 AHA Guidelines. This intervention was associated with a 90% relative increase in overall survival. We believe this is the first report to show an improvement in OHCA survival by achieving the 2010 AHA CPR Guidelines.
The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder
Cameron, Anne P., Chung, Doreen E. , Dielubanza, Elodi , Enemchukwu, Ekene , Ginsberg, David A. , Linder, Brian J. , Rovner, Eric S., Souter, Lesley , Welk, Blayne , Cameron, Anne P. , Linder, Brian J , Helfand, Brian T. , Reynolds, William M. , Suskind, Anne M. , Takacs, Elizabeth B. , Smith, Ariana L.

Mayo Clinic

Journal of Urology | April 23, 2024 | Volume: 212 | Issue: 1 | Pages: 11-20

10.1097/ju.0000000000003985 | PMID 38651651 Get It

Mind the Gap! Working Toward Gender Equity in Pediatric and Congenital Heart Disease: Present and Future
Chowdhury, Devyani , Bansal, Neha , Ansong, Annette , Baker‐Smith, Carissa M. , Choueiter, Nadine , Co‐Vu, Jennifer , Elliott, Pietro , Fuller, Stephanie , Jain, Supriya , Johnson, Jonathan N. , Karamlou, Tara , Kipps, Alaina K. , Laraja, Kristin, Rasheed, Muneera A. , Ronai, Christina , Sachdeva, Ritu , Snyder, Christopher S. , Sutton, Nicole , Stiver, Corey, Shaffer, Kenneth M. , Williams, Roberta G. , Baker-Smith, Carissa M , Co-Vu, Jennifer , Elliott, Pietro , Fuller, Stephanie , Jain, Supriya S , Jone, Pei-Ni , Johnson, Jonathan , Kipps, Alaina K , Lopez, Keila N , Rasheed, Muneera , Ronai, Christina , Sachdeva, Ritu , Snyder, Chris , Sutton, Nicole , Taggart, Nathaniel W , Shaffer, Kenneth , Williams, Roberta , Bauser‐Heaton, Holly , Lopez, Keila N. , Saidi, Arwa S. , Taggart, Nathaniel W.

Mayo Clinic

Journal of the American Heart Association | April 19, 2024 | Volume: 13 | Issue: 9 | Pages: No page available

10.1161/jaha.123.032837 | PMID 38639355 Get It

Evidence from medicine and other fields has shown that gender diversity results in better decision making and outcomes. The incoming workforce of congenital heart specialists (especially in pediatric cardiology) appears to be more gender balanced, but past studies have shown many inequities. Gender‐associated differences in leadership positions, opportunities presented for academic advancement, and recognition for academic contributions to the field persist. In addition, compensation packages remain disparate if evaluated based on gender with equivalent experience and expertise. This review explores these inequities and has suggested individual and institutional changes that could be made to recruit and retain women, monitor the climate of the institution, and identify and eliminate bias in areas like salary and promotions.
Stripping versus ligation of vas deferens in microscopic denervation of spermatic cord in men with chronic orchialgia: A multicenter study
El‐Achkar, Adnan , Hammad, Muhammed , Barham, David , Service, C Austin, Hsieh, Tung- Chin, Mills, Jesse N. , Ziegelmann, Matthew , Smith, Ryan P. , Bernie, Helen L. , Egert, Melissa , Gross, Kelli, Pastuszak, Alex, Hotaling, James M. , Yafi, Faysal A. , Hammad, Muhammed A M , Patel, Darshan P. , Kianian, Reza , Eleswarapu, Sriram Venkata , Bryk, Darren J. , Raheem, Omer A. , Fendereski, Kiarad

Mayo Clinic

Andrology | April 19, 2024 | Volume: 13 | Issue: 2 | Pages: 268-274

10.1111/andr.13650 | PMID 38639020 Get It

AbstractBackgroundMicrodenervation of the spermatic cord (MSCD) is an effective treatment modality for men with intractable scrotal content pain. For patients not interested in preserving fertility, some centers advocate ligation of the vas during denervation, while others prefer stripping of the vas deferens to preserve the vasal artery, hence preserving vasculature to the testis and possibly decreasing post‐operative congestion pain.ObjectiveTo compare outcomes of patients with chronic orchialgia, who underwent MSCD by either stripping or ligating the vas deferens.Materials and methodsA retrospective chart review of 85 patients who underwent MSCD from 2017–2023 was performed. Patients’ demographics including history of prior surgical procedures were recorded. Response to surgery was evaluated as either complete resolution of pain, partial resolution of pain, or no improvement in pain.ResultsEighty‐five patients underwent MSCD with a median (interquartile range, IQR) age of 36 (25.5–46.5) years and median duration of pain of 16 (6–31) months. Thirty‐seven patients underwent stripping of vas, while 48 underwent ligation of vas during MSCD. Median follow up was 12 months. Twenty‐one (43.5%) patients had prior inguinal scrotal surgery in the ligation group compared to 5 (13.5%) in the stripping group, p = 0.003. The etiology of pain was similar between the groups. The response to MSCD between the two groups was similar, 67.6% of patients who underwent stripping had complete resolution of pain versus 66.7% of those who had ligation (p = 0.968), with similar rates of post‐operative complications (p‐value = 0.132).ConclusionsIn men with intractable chronic scrotal content pain with no interest in preserving fertility, ligation, or stripping of the vas deferens yields similar outcomes with regard to pain resolution. Both techniques are safe with no reports of any testicular atrophy.